Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy of heart function improvements in type 2 diabetes and heart failure patients with exenatide, and also investigates the mechanisms of exenatide improving heart function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
• Treatments: Exenatide

Criteria

Inclusion Criteria:

1. Diagnosed Type 2 diabetes mellitus

2. HbA1c 7%-10% and Fasting plasma glucose(FBG) <10mmol/L

3. Age 18-65 years

4. NT-proBNP level≥ 450 pg/ml

5. Left ventricular ejection fraction (LVEF)<40%

Exclusion Criteria:

1. Uncorrected primary vascular disease

2. congenital heart disease

3. Left ventricular outflow obstruction

4. Myocarditis

5. Aneurysm

6. uncontrolled severe arrhythmia

7. cardiogenic shock

8. unstable angina, or acute myocardial infarction

9. Severe primary hepatic, renal, or hematologic disease

10. Cr>194.5 mmol/l or K+>5.5 mmol/l

11. Systolic blood pressure (SBP) ≥180mm Hg or diastolic blood pressure (DBP) ≥110mm Hg

12. Alanine aminotransferase (ALT) >3 times the upper normal limit

13. Patients were likely to undergo coronary artery bypass graft surgery during the following 4 weeks

14. Patients had undergone or were likely to undergo cardiac resynchronization therapy

15. Pregnant or lactating known

16. Suspected to be allergic to the study drugs

17. Use dipeptidyl peptidase-4 (DPP-4) or glucagon-like peptide-1 (GLP-1) drug in 3 months

18. Hyperthyroidism and Hypothyroidism

19. Tumor

20. Received another investigational drug within 30 days prior to randomization

21. Severe mental health condition or other uncontrolled systemic disease.